[대학원 생명과학과 세미나 안내]
연사 : 김수정 박사(코오롱생명과학)
연제 : Invossa, a gene-modified cell therapy for osteoarthritis: from research to commercialization
일시 : 2018년 9월 28일 (금) 오후 5시
장소 : 하나과학관 A동 B131호
초청교수 : 백경희 교수
Abstract
Osteoarthritis is the most common form of arthritis, affecting millions of people around the world. It is induced by gradual damage, degeneration, accident or other diseases of cartilage in the joint. Conservative therapies, such as physical therapy, oral NSAID and intra-articular injections are used to manage OA, however, disease control often remains inadequate.
Invossa is an allogeneic cell and gene therapy for OA. It is a mixture of allogeneic chondrocytes and genetically modified chondrocytes to express TGF-b1. TGF-b1 is a multi-functional cytokine. It can suppress immune response, and induce differentiation and proliferation of chondrocytes.
OA had traditionally been considered as a non-inflammatory arthritis; however, this concept has been changed recently. It has been shown that the immune response is critical for the development of OA, and chronic inflammation is found in OA joint. Invossa changes the immune environment of OA joint from inflammatory to anti-inflammatory condition by inducing polarization of anti-inflammatory M2 macrophages. Invossa can control pain and OA symptoms by controlling inflammation, and can create environment favorable for cartilage repair. Clinical trials have shown that Invossa treatment improved pain and function in OA patients for 1 year with a single intra-articular injection. Invossa was approved for knee OA in Korea on July 12, 2017.